Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?
a Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.
Ahmet Emre
AE
Eskazan
a Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.
Muhlis Cem
MC
Ar
a Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.
Teoman
T
Soysal
D000970:Antineoplastic Agents; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D047428:Protein Kinase Inhibitors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate
Chronic myeloid leukemia; failure; imatinib; optimal response; suboptimal response; tyrosine kinase inhibitor; warning